Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

F1308

Sigma-Aldrich

Fosinopril sodium

≥98% (HPLC), powder

Sinónimos:

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C30H45NO7P · Na
Número de CAS:
88889-14-9
Peso molecular:
585.64
MDL number:
MFCD23704184
UNSPSC Code:
12352200
PubChem Substance ID:
329799677
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: >20 mg/mL

originator

Bristol-Myers Squibb

storage temp.

−20°C

SMILES string

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

InChI key

TVTJZMHAIQQZTL-TXDYNIFHSA-M

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.

Biochem/physiol Actions

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Disposition of fosinopril sodium in healthy subjects
Singhv SM, et al.
British Journal of Clinical Pharmacology, 25(1), 9-15 (1988)
S Giovannini et al.
The journal of nutrition, health & aging, 14(6), 457-460 (2010-07-10)
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial
Dinesh Shrikrishna et al.
Chest, 146(4), 932-940 (2014-02-22)
Skeletal muscle impairment is a recognized complication of COPD, predicting mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in control of muscle phenotype. We hypothesized that angiotensin-converting enzyme (ACE) inhibition would improve quadriceps function and exercise performance in
Patrick Rossignol et al.
Hypertension (Dallas, Tex. : 1979), 60(2), 339-346 (2012-07-11)
Optimal blood pressure (BP) targets are still controversial in end-stage renal disease. Recent data have highlighted shortcomings of the usual BP hypothesis in other patient populations and emphasized the importance of visit-to-visit variability of BP in predicting cardiovascular events. The
Ya-chen Zhang et al.
Cell biochemistry and biophysics, 64(3), 205-211 (2012-06-26)
Fosinopril, an angiotensin-converting enzyme inhibitor, is known to attenuate cardiomyopathy induced by doxorubicin (DOX); however, the mechanisms of this cardioprotection are not fully elucidated yet. In the present study, experimental cardiomyopathy was induced in rats by administration of DOX with
Ver todos los artículos relacionados

Artículos

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico